AGIOS PHARMACEUTICALS, INC. Cash Provided by (Used in) Financing Activities, Discontinued Operations
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Cash Provided by (Used in) Financing Activities, Discontinued Operations of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations · last filed 2023-02-23
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2022-12-31 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2022-09-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2022-06-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2022-03-31 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for fiscal 2022 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for fiscal 2020 was $250.54M.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for fiscal 2019 was $0.00.
| Period end | Cash Provided by (Used in) Financing Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 6 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 9 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 4 quarters · filed 2023-02-23 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $0.00 derived: sum of 4 quarters · filed 2023-02-23 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $0.00 derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $0.00 derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 derived: sum of 3 quarters · filed 2023-02-23 | $250.54M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $250.54M derived: sum of 3 quarters · filed 2023-02-23 | $250.54M 10-K · filed 2023-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $250.54M derived: sum of 2 quarters · filed 2021-11-03 | $250.54M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $250.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $250.54M 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-04-29 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |